louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06929858: Effect of Cognitive-Behavioral Strategies on Nurses Caring for Children With Autism Spectrum Disorder
Official title: Effect of Cognitive-Behavioral Strategies on Self-Efficacy, Sense of Coherence, and Psychological Ownership Among Nurses Caring for Children With Autism Spectrum Disorder
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Nurses Behaviors
Lead sponsor: Port Said University
Sponsor class: OTHER
First posted: 2025-04-16
Enrollment: 92
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine if a structured training program in cognitive-behavioral strategies can improve:

Self-efficacy: The belief in one's ability to succeed in specific tasks or situations.

Sense of coherence: A perception of life as comprehensible, manageable, and meaningful.

Psychological ownership: A sense of possession or attachment to one's job or role.

These outcomes are critical for nurses working with children with ASD, as their role involves unique emotional and professional challenges. The study will use a rigorous scientific approach to assess the effectiveness of the intervention.


Eligibility criteria: Registered nurses who provide direct care to children with ASD in settings such as hospitals, clinics, or specialized care centers.

Inclusion Criteria:

* At least 6 months of experience caring for children with ASD.
* Currently employed in a direct caregiving role for these children.

Exclusion Criteria:

* Nurses with prior formal training in cognitive-behavioral therapy.
* Nurses planning to leave their position during the study period.

Primary outcomes:
measure: Self-Efficacy
timeFrame: 2 months
Secondary outcomes:
measure: Sense of Coherence
timeFrame: 2 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00546858: Relationship of Interstitial Cystitis to Vulvodynia
Official title: Part A: STUDY OF THE RELATIONSHIP OF INTERSTITIAL CYSTITIS TO VULVODYNIA
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Interstitial Cystitis
Keywords: Pelvic pain
Vulvar pain
Lead sponsor: William Beaumont Hospitals
Sponsor class: OTHER
First posted: 2007-10-19
Enrollment: 350
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a diagnosis of Interstitial Cystitis from the practices of Dr Ananias Diokno and Dr Kenneth Peters will be mailed a survey.

Brief summary: This study is important in urologic nursing since many patients have interstitial cystitis (IC), a condition of frequency, urgency and pain affecting more than 1 million women in the United States. The vulva may actually be the site of some of the reported pain in women with IC, not the urethra or bladder. IC and vulvodynia can impact one's sexual functioning and diminish one's quality of life.

The purpose of this two-part study is to identify and clinically confirm the presence of vulvodynia in women diagnosed with Interstitial Cystitis (IC).


Eligibility criteria: Inclusion Criteria:

* Females who are 18 years of age and older.
* Diagnosis of interstitial cystitis

Primary outcomes:
measure: The purpose of this two-part study is to identify and clinically confirm the presence of vulvodynia in women diagnosed with Interstitial Cystitis (IC).
timeFrame: Prospective
Secondary outcomes:
Other outcomes:
Locations:
city: Royal Oak
country: United States
facility: William Beaumont Hospital
state: Michigan
Study officials:
affiliation: William Beaumont Hospitals
name: Donna Carrico, NP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00770458: Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
Official title: Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Down Syndrome (Trisomy 21)
Edwards Syndrome (Trisomy 18)
Patau Syndrome (Trisomy 13)
Turner Syndrome
Keywords: Down Syndrome
Lead sponsor: Sequenom, Inc.
Sponsor class: INDUSTRY
First posted: 2008-10-10
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Fetal care and genetic counseling patients.

Brief summary: Validate that circulating cell free fetal nucleic acid can be used to identify a direct marker for fetal aneuploidy, particularly fetal Down Syndrome (DS), that is better than surrogate markers.


Eligibility criteria: Inclusion Criteria:

* Subject is female
* Subject is pregnant
* Subject is high risk aneuploid patient undergoing genetic counseling, unltrasound screening, amniocentesis and/or CVS procedure
* Subject is willing to provide blood specimen

Exclusion Criteria:

* Subject is not pregnant
* Subject is not willing to provide blood specimen
* Subject is not haveing aneuploid screening

Primary outcomes:
measure: Compare investigational assay results for Down Syndrome to standard of care results.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD Fetal Care & Genetics Center
state: California
city: San Diego
country: United States
facility: San Diego Perinatal Center
state: California
city: San Jose
country: United States
facility: Obstetrix Medical Group of San Jose
state: California
city: Denver
country: United States
facility: Obstetrix Medical Group of Colorado
state: Colorado
city: Providence
country: United States
facility: Women & Infants
state: Rhode Island
city: Salt Lake City
country: United States
facility: A.R.U.P.
state: Utah
city: Seattle
country: United States
facility: Obstetrix Medical Group of Washington
state: Washington
Study officials:
affiliation: Sequenom, Inc.
name: Allan Bombard, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04146558: Ayurvedic Treatment Package in Plaque Psoriasis
Official title: A Randomized Open Label Clinical Trial on the Efficacy of an Ayurvedic Treatment Package on Symptom Severity and Quality of Life in Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Psoriasis
Lead sponsor: Universität Duisburg-Essen
Sponsor class: OTHER
Collaborators: name: Poomulli Neelakandan Namboodiripad Memorial Ayurveda Medical College
First posted: 2019-10-31
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Psoriasis is a chronic, immune-mediated inflammatory skin disease that is associated with substantial impairment of physical and psychological quality of life. The conventional treatment protocols manages the condition but with remissions and relapses which create anxiety in patients. Many of the patients withdraw from active social life as the disease attains chronicity. Several studies are pointing towards a conjoint management strategy incorporating the traditional and alternate medical systems. In this regard, Ayurveda is commonly used by psoriatic patients in India. Considering this fact it is high time to conduct a study to scientifically evaluate the efficacy of Ayurvedic treatment protocol in managing psoriasis as well as its potential to improve the quality of life.


Eligibility criteria: Inclusion Criteria:

* Patients with psoriasis having age 18 years or more
* Patients with moderate-to-severe plaque psoriasis with a PASI score of 12 or higher
* Psoriasis diagnosed 6 months or more before study entry
* Those who are poorly controlled based on physicians assessment with topical treatments, phototherapy, systemic therapy, or a combination of these therapies.
* Participants who have given informed consent.

Exclusion Criteria:

* Participants with other systemic illnesses
* Lactating and pregnant mothers.
* Alcohol dependence/Narcotic dependence /Steroid dependence
* In the judgment of the investigator, unable or unwilling to follow the protocol and instructions

Primary outcomes:
measure: Psoriasis-specific quality of life
timeFrame: 6 months
Secondary outcomes:
measure: Psoriasis Severity
timeFrame: 3 months
measure: Psoriasis Severity
timeFrame: 6 months
measure: Psoriasis Severity
timeFrame: 12 months
measure: Psoriasis-specific quality of life
timeFrame: 3 months
measure: Psoriasis-specific quality of life
timeFrame: 12 months
measure: Adverse events
timeFrame: 3 months
measure: Adverse events
timeFrame: 6 months
measure: Adverse events
timeFrame: 12 months
Other outcomes:
Locations:
city: Shoranur
country: India
facility: PNNM Ayurveda College
state: Kerala
Study officials:
References:
Clinical trial NCT00537758: Treatment for Obesity and Binge Eating Disorder
Official title: Treatment for Obesity and Binge Eating Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Binge Eating Disorder
Obesity
Keywords: binge eating disorder
cognitive behavior therapy
combination therapy
obesity
weight loss
body weight
clinical trial
dietary restriction
overeating
weight control
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2007-10-01
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a test of cognitive behavioral therapy(CBT) and behavioral weight loss (BWL) treatments for obese patients with binge eating disorder (BED). The study involves a comparison of three treatment conditions: (1) CBT; (2) BWL, and (3) a sequential (two-part) treatment consisting of CBT followed by BWL.


Eligibility criteria: Inclusion Criteria:

* Binge Eating
* Overweight

Exclusion Criteria:

* Pregnancy
* Current cardiac disease
* Serious neurologic illnesses

Primary outcomes:
measure: Binge Eating
measure: BMI
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale Psychiatric Research at Congress Place
state: Connecticut
Study officials:
affiliation: Yale University
name: Carlos M. Grilo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01274858: Sensory Mapping and Thermal Thresholds After Thoracic Surgery
Official title: Sensory Mapping and Thermal Thresholds After Thoracic Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Keywords: persistent pain
neuropathic pain
Thoracotomy
Chronic Pain
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2011-01-12
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lung cancer patients

Brief summary: The study will investigate topography of sensory changes late after lung cancer surgery


Eligibility criteria: Inclusion Criteria:

* Understand Danish
* Age \> 18 years old
* PTPS

Exclusion Criteria:

* Cognitive dysfunction
* Repeated thoracic surgery
* Nerve injury from other causes
* Drug or alcohol abuse

Primary outcomes:
measure: Thermal thresholds (Quantitative Sensory Testing [QST])
timeFrame: average 18 months after surgery
measure: Sensory mapping
timeFrame: average 18 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
city: Copenhagen
country: Denmark
facility: Section for Surgical Pathophysiology 4074
Study officials:
References:
citation: Werner MU, Ringsted TK, Kehlet H, Wildgaard K. Sensory testing in patients with postthoracotomy pain syndrome: Part 1: mirror-image sensory dysfunction. Clin J Pain. 2013 Sep;29(9):775-83. doi: 10.1097/AJP.0b013e318277b646.
Clinical trial NCT02338258: The Study of the Nonunion of Long Tubular Bone
Official title: The Prospective、Randomized、Comparative Clinical Study About the Two Operation Methods Between Anti-rotational Plate Group and Exchanged Intramedullary Nailgroup to Treat the Nonunion of Long Tubular Bone After Intramedullary Nail Fixation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Diaphyses
Lead sponsor: Beijing Jishuitan Hospital
Sponsor class: OTHER
First posted: 2015-01-14
Enrollment: 82
Sex: ALL
Minimum age (years): 14
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study to supplied the diagnostic and treatment criteria of the nonunion of the long tubular bone after treatment of Intramedallery nailing


Eligibility criteria: Inclusion Criteria:

1. The patient who had the nonunion of long tubular bone
2. The patient who was the age of 14 \~ 65 years old.
3. The patient who complete the follow-up conditions.
4. The patient who has independent behavior ability.
5. The patient who volunteered for signed informed consent

Exclusion Criteria:

1. Infectious nonunion of the long turubar bone
2. Pathological fracture.
3. The immune system disease.
4. Cancer

Primary outcomes:
measure: The healing rate
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: The orthopaedic Trauma center of Jishuitan Hospital in Beijing
state: Beijing
Study officials:
affiliation: Jishuitan hospital in Beijing
name: Bosong Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05681858: Plaque Burden and Ischemia in MINOCA
Official title: Coronary Artery Plaque, Perivascular Inflammation and Myocardial Ischemia in Patients With Myocardial Infraction and Non-obstructive Coronary Arteries
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: MINOCA
Lead sponsor: University of Bergen
Sponsor class: OTHER
Collaborators: name: Haukeland University Hospital
name: Haraldsplass Deaconess Hospital
First posted: 2023-01-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients hospitalized with acute myocardial infarction and non-obstructive coronary artery disease by coronary angiography

Brief summary: The goal of this clinical trial is to assess coronary artery plaque burden, perivascular inflammation and extent of myocardial ischemia in patients presenting with acute myocardial infarction and non-obstructive coronary artery disease. The main question it aims to answer are:

* Identify coronary artery anatomy, plaque burden, composition and high-risk plaque features by CT coronary angiography in MINOCA
* Assess presence, extent and severity of myocardial ischemia in MINOCA

Participants will examined by CT coronary angiography and stress \[12N\] NH3 PET-MR.


Eligibility criteria: Inclusion Criteria:

* Acute chest pain
* Elevated troponin
* Non-obstructive coronary arteries by coronary angiography

Exclusion Criteria:

* Obstructive coronary artery disease
* Contraindications against CT coronary angiography or stress \[12N\] NH3 PET-MR
* Not able to give informed consent

Primary outcomes:
measure: Plaque burden
timeFrame: 1 week
measure: Myocardial ischemia
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: Department of Clinical Science, University of Bergen
Study officials:
References:
Clinical trial NCT05559658: Comprehensive Assessment in a Longitudinal Study on Young Men Who Have Sex With Men Attracting to chemseX
Official title: A Cross-sectional Descriptive Study Using Mixed Method (Qualitative and Quantitative) Data Collection
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: ChemSex Users for YMSM
ChemSex Users
Keywords: ChemSex users
Lead sponsor: Institute of HIV Research and Innovation Foundation, Thailand
Sponsor class: OTHER
Collaborators: name: amfAR, The Foundation for AIDS Research
First posted: 2022-09-29
Enrollment: 60
Sex: MALE
Minimum age (years): 16
Maximum age (years): 35
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Current chemsex users

Brief summary: The study is a two-phase observational study that assess multiple aspects of study and young men who have sex with men (YMSM).

Phase I of the study will be a cross-sectional descriptive study using a mixed methods data collection (focusing on qualitative data collection) to acquire information necessary for developing a more extensive study on the same matter.

Phase II of the study will be a prospective cohort study using a quantitative data collection.

Findings from phase I will guide the development of phase II which consist of a larger number of YMSM, important baseline and follow-up questionnaires and comorbidities assessments, sexually transmitted infections testing, and integration to care.

This protocol exclusively addresses the phase I of the study.

Once the phase I findings are finalized, the principal investigator will submit the phase II to the IRB of the Faculty of Medicine, Chulalongkorn University.


Eligibility criteria: Inclusion Criteria:

Group 1A: Current chemsex users

1. Men who have sex with men
2. Aged 16-35 years
3. Able to communicate in Thai fluently
4. Current chemsex users
5. Provide informed consent

Inclusion Criteria:

Group 1B: Former chemsex users (discontinued ≥90 days)

1. Men who have sex with men
2. Aged 16-35 years
3. Able to communicate in Thai fluently
4. Former chemsex users (discontinued ≥90 days)
5. Provide informed consent

Exclusion Criteria:

No exclusion criteria for all groups of participants

Primary outcomes:
measure: The study will be divided into two phases. The information on the procedures of the phase I single study visit is presented below.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Pathum wan
country: Thailand
facility: Institute of HIV Research and Innovation
state: Bangkok
Study officials:
References:
Clinical trial NCT01576458: Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy
Official title: Randomised Placebo-controlled Study of Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Intrahepatic Cholestasis
Pregnancy
Keywords: ursodeoxycholic acid
intrahepatic cholestasis
pregnancy
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2012-04-12
Enrollment: 20
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the efficacy and safety of ursodeoxycholic acid (UDCA) in the treatment of patients with intrahepatic cholestasis of pregnancy (ICP).

In the randomised (double-blind, placebo-controlled) study 20 pregnant women with ICP received (random allocation of) either 450 mg/day UDCA or placebo for 14 days during the third trimester of pregnancy. The severity of pruritus was registered. Itching scores and serum levels of alanine aminotransferase, total bile acids, estradiol, progesterone, prolactin, cholesterol, HDL-cholesterol, triglycerides, activated partial thromboplastin time (APTT), fibrinogen D-dimers (FIDD) and platelet count were assessed before the treatment and weekly thereafter. Data on pregnancy and delivery outcome was recorded and analysed.


Eligibility criteria: Inclusion Criteria:

* Pregnant women with intrahepatic cholestasis of pregnancy

Primary outcomes:
measure: pruritus
timeFrame: an average of 5 weeks
measure: laboratory values
timeFrame: an average 5 weeks
Secondary outcomes:
measure: Obstetrical surveillance
timeFrame: 2-12 weeks
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
affiliation: Turku University Hospital
name: Susanna Timonen, PhD
role: STUDY_CHAIR
affiliation: Turku University Hospital
name: Ulla Ekblad, PhD
role: STUDY_DIRECTOR
affiliation: Turku University Hospital
name: Riitta Leino, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Turku University Hospital
name: Pertti Palo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Joutsiniemi T, Timonen S, Leino R, Palo P, Ekblad U. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Arch Gynecol Obstet. 2014 Mar;289(3):541-7. doi: 10.1007/s00404-013-2995-5. Epub 2013 Aug 27.
Clinical trial NCT01254058: Saccadic Eye Movements Are Impaired In Glaucoma
Official title: Novel Vision Testing Paradigms for Patients With Glaucoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Glaucoma, Open-Angle
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2010-12-06
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 19 glaucoma patients and 21 age-matched controls will be identified and consented.

Brief summary: The purpose of this study is to determine whether rapid eye movements called saccades are impaired in glaucoma, a neurodegenerative disease of visual pathways.

Detailed description: Eye movements that quickly scan a visual scene are critical to a number of daily activities including driving. It is not known whether rapid eye movement called saccades, are altered in glaucoma.

Eligibility criteria: Inclusion Criteria:

* Ages from 40-80 years. Primary open angle glaucoma is defined by characteristic glaucomatous optic nerve head findings and the presence of corresponding visual field deficits in one or both eyes. All control subjects will be age-matched, with no ocular medical or surgical history, and a completely normal eye examination. Age-matched controls will be recruited from local hospital personnel and accompanying relatives.

Exclusion criteria:

* Any patient with a history of other eye disease, neurological disease or neurodegenerative disorder, or history of incisional ocular surgery within the previous month will be excluded.

Primary outcomes:
measure: Delay in saccades
timeFrame: April 2014
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Neeru Gupta, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gupta N, Krishnadev N, Hamstra SJ, Yucel YH. Depth perception deficits in glaucoma suspects. Br J Ophthalmol. 2006 Aug;90(8):979-81. doi: 10.1136/bjo.2006.091025. Epub 2006 May 3.
citation: Kanjee R, Yucel YH, Steinbach MJ, Gonzalez EG, Gupta N. Delayed saccadic eye movements in glaucoma. Eye Brain. 2012 Nov 26;4:63-68. doi: 10.2147/EB.S38467. eCollection 2012.